IPM Take
ALS research does not need more scientific excitement that cannot survive a real trial.
It needs evidence that connects biology to what people are actually losing: speech, movement, swallowing, breathing, independence and time with the people they love. PrimeC’s reported effect on neuron-derived TDP-43 is a meaningful signal because TDP-43 sits close to the biology of ALS. But no biomarker should be allowed to carry more political weight than it has earned.
The promise is real. The proof still has to become harder.
Executive Summary
NeuroSense reported that PrimeC met a prespecified primary biomarker endpoint in its Phase 2b PARADIGM study, with a statistically significant reduction in neuron-derived TDP-43 compared with placebo at Day 180: p=0.0421.
The company said the difference was maintained through Day 540 among participants who remained on active treatment. PrimeC is an investigational fixed-dose combination of ciprofloxacin and celecoxib designed to address several pathways implicated in ALS.
The broader PARADIGM trial has been published in JAMA Neurology. That peer-reviewed report described a randomised Phase 2b study that was not powered to establish definitive clinical efficacy. The new TDP-43 update is company-reported and should be treated as supportive biological evidence, not confirmation that PrimeC changes the disease course.
Why it matters
- Patients / advocates: ALS families need urgency. They also need evidence that makes clear whether a treatment changes the disease rather than only a laboratory measure.
- Clinicians: TDP-43 target engagement is biologically relevant, but clinical value will depend on whether later trials confirm functional and survival benefit.
- Researchers / academia: Neuron-derived extracellular-vesicle biomarkers may become useful trial tools, but they require validation, reproducibility and clear clinical interpretation.
- Regulators: A disease-linked biomarker can strengthen a development programme. It cannot replace evidence that patients live better or decline more slowly.
ALS takes away things that health systems often fail to value until they are gone.
A hand stops working. Speech becomes slower. Swallowing becomes dangerous. Breathing becomes labour. The person is still there, while the body becomes less able to answer.
That is why ALS drug development cannot afford weak evidence dressed up as hope.
PrimeC’s TDP-43 result deserves attention because it is linked to a protein pathology central to most ALS cases. Showing that a treatment changes a disease-relevant biomarker in a randomised study is not trivial. It may help explain why a therapy should move forward.
But ALS has seen too many promising signals that failed once the evidence standard became serious.
The responsible interpretation is straightforward. PrimeC has generated a biologically interesting result, supported by a peer-reviewed Phase 2b trial and a new company-reported biomarker analysis. That is enough to justify rigorous further testing. It is not enough to declare that ALS now has a disease-modifying answer.
The next trial has to do the harder thing. It has to show that the biology becomes preserved function, fewer complications, longer survival and more time returned to patients.
ALS does not need another candidate that looks good in fragments. It needs evidence that holds together.
